You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.
Novitas added multiple leukemia biomarkers to its coverage determination, as well as the ThyGeNEXT molecular panel.
The tests are covered when the patient has a personal history of melanoma and the test has demonstrated clinical and analytical validity.
The GenomeWeb Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all fell in October.
The test assesses multiple factors, including single-/multi-nucleotide variants, short insertions and deletions, and microsatellite instability status.
Under the LCD, oncology biomarkers must have proven clinical validity and there must be acceptance of specific testing into patient management.
The general LCD is covered for patients with a personal history of melanoma undergoing workups or being evaluated for treatment without metastatic disease.
The firm said that it has secured coverage for about 100 million lives for its targeted NGS liquid biopsy test in the US between Medicare and private payors.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.